Program – 7th Global Forum – Global Forum on TB Vaccines

Programa

With an overarching theme of "Impulsando la innovación desde el descubrimiento hasta el acceso," the 7th Global Forum program covered the full spectrum of research and development, from basic and discovery research to diversify the TB vaccine pipeline through clinical research. With multiple candidates now advancing through late-stage clinical trials, we also explored strategies to ensure new TB vaccines reach the populations that most need them and to maximize the public health impact. This focus on end-to-end development provided a unique opportunity for participants to hear diverse perspectives and learn and engage with experts from across the field.

El programa del 7^o Global Forum on TB Vaccines was developed around five thematic tracks. These thematic tracks align with the Marco estratégico para el desarrollo de una vacuna contra la tuberculosis en el Plan mundial para acabar con la tuberculosis 2023-2030, la EDCTP/AIGHD Hoja de ruta mundial para la investigación y el desarrollo de vacunas contra la tuberculosis, and the WHO's Marco global para prepararse para la introducción nacional de nuevas vacunas contra la tuberculosis para adolescentes y adultos.

Obtenga más información sobre las pistas temáticas aquí.

Haga clic aquí to view the program-at-a-glance.

Click on the "Details" box under each session to view abstracts (oral abstract sessions only) as well as speaker presentations where permission was granted to post them.

Haga clic aquí to view poster abstracts as well as posters where permission was granted to post them.

Click the dates to see a specific daily program

Tue, 8 Oct 2024

Wed, 9 Oct 2024

Thu, 10 Oct 2024

Fri, 11 Oct 2024

Tuesday, 8 October 2024

08:30 - 10:00

Registration | Coffee | Networking

10:00 - 12:30

Grande Sala

Opening Session & Keynote Address

Details

Session Chairs: Ethel Maciel, Ministry of Health (Brazil) | David Lewinsohn, Stop TB Partnership Working Group on New TB Vaccines (USA)

Welcome and Opening Remarks
Sania Nishtar, CEO, Gavi, the Vaccine Alliance (Switerland) (recorded remarks)
Mark Feinberg, President and CEO, IAVI (USA)
Miguel Aragon, Coordinator of the Communicable Diseases and Environmental Determinants of Health Unit, PAHO/WHO (Brazil)
Ricardo Alexandre Arcêncio, President, REDE-TB (Brazil)
Daniel Soranz, Secretary of Health of Rio de Janeiro (Brazil)

Keynote Address
Jeremy Farrar, Chief Scientist, World Health Organization (Switzerland)

Panel: How to make TB vaccines a reality
Ethel Maciel, Secretary of Health Surveillance and Environmental Health, Ministry of Health (Brazil)
Suvanand Sahu, Deputy Executive Director, Stop TB Partnership (Switzerland)
Ruben Rizzi, Vice President, Global Regulatory Affairs, BioNTech (Germany)
Mario Moreira, President, Fiocruz (Brazil)
Nina Russell, Director, TB & HIV Research and Development, Bill & Melinda Gates Foundation (USA)

Community Declaration
Paulina Siniatkina, TBpeople and KNCV TB Plus (Netherlands)

12:30 - 13:30

Almuerzo

13:30 - 15:00

Grande Sala

Plenary 1: From discovery to access

Details

Session Chairs: Ana Paula Junqueira-Kipnis, Federal University of Goiás; REDE-TB (Brazil) | Gerald Voss, TuBerculosis Vaccine Initiative (TBVI) (Netherlands)

Diversifying the TB vaccine pipeline
Elly van Riet, TBVI, (Netherlands)
Presentation

Clinical development of new TB vaccines: State of the field
Elana van Brakel, IAVI (South Africa)
Presentation

Preparing for implementation and ensuring public health impact - leveraging the TB Vaccine Accelerator
Birgitte Giersing, Immunization, Vaccines and Biologicals, World Health Organization (Switzerland)
Presentation

Accelerating the TB vaccine pathway - from bench to communities
Soumya Swaminathan M S Swaminathan Research Foundation (India) (recorded)
Presentation

Community perspsective
Ezio Távora, REDE-TB (Brazil)

15:00 - 16:30

Grande Sala Foyer

Break | Poster Viewing

Haga clic aquí to view a list of posters and abstracts, as well as posters where permission was granted to post them.

16:30 - 18:00

Grande Sala

Plenary 2: Global and regional enablers for the introduction of new TB vaccines

Details

Session Chairs: Richard White, London School of Hygiene and Tropical Medicine (UK) | Julio Croda, Fundação Oswaldo Cruz / Rede-TB (Brazil)

Presentations and Speakers

Manufacturer's Perspective
Roseane Cuber, Bio-Manguihos/Fiocruz (Brazil)
Presentation

Introduction of new TB vaccines: What should we consider?
Eder Gatti, National Immunization Program (Brazil)
Presentation

Gavi's role in the global countdown to introducing new TB vaccines
Marta Tufet Bayona, Gavi, the Vaccine Alliance (Switzerland)

Community preparedness: From port to arm for rapid introduction and scale-up of new TB vaccines
Peter Owiti Ngo'la, Gavi CSO Constituency (Kenya)
Presentation

Key principles to ensure equitable TB vaccine access to maximize health impact
Rupali Limaye, Johns Hopkins Bloomberg School of Public Health (USA)
Presentation

18:00 - 20:00

Recepción de bienvenida

Wednesday, 9 October 2024

08:30 - 09:00

Arrival | Coffee | Networking

09:00 - 11:00

Grande Sala

Plenary 3: Advancing TB vaccine clinical development: Learning from experience and looking to the future

Details

Session Chairs: Ann Ginsberg, Bill & Melinda Gates Foundation (USA) | Valeria Rolla, INI-Fiocruz (Brazil)

Efficacy, safety & immunogenicity of H56:IC31 vaccine for prevention of recurrent TB
Thomas Scriba, University of Cape Town (South Africa)

BCG revaccination: Lessons learned and implications for the field
Alexander Schmidt, Gates Medical Research Institute (USA)
Presentation

MTBVAC, late stage clinical development
Ingrid Murillo Jelsbak, Biofabri, SLU (Spain)
Presentation

Subclinical TB: implications for TB vaccine trial designs and development
Gavin Churchyard, Aurum Institute (South Africa)
Presentation

Community perspective
Keyuri Bhanushali, Survivors Against TB (India)

11:00 - 11:30

Pausa

11:30 - 13:00

Oral Abstract Sessions

Grande Sala

OA1: Mechanisms of biomarkers and protection, novel approaches, human challenge, optimizing animal models

Details

Session Chairs: Lewis Schrager, IAVI (USA) | Maiko Tonini, Ministry of Health (Brazil)

OA-01. Lymph nodes as niches for Tuberculosis micobacteriana infection in humans and profiling of associated host immune responses
Carly Young-Bailie, University of Cape Town (South Africa)
Abstract | Presentation

Macro meets T: Signaling Lymphocyte Activation Molecule Family Member 1 (SLAMF1) promotes protective immunity against mtb through Macrophage-T cell interaction
G V R Krishna Prasad, Washington University in St. Louis (USA)
Abstract | Presentation

Systems biology of rBCG-LTAK63 immunization highlights correlation between circadian rhythm, immune response, and protection against tuberculosis
Lazaro Moreira Marques-Neto, Instituto Butantan (Brazil)
Abstract | Presentation

M. tuberculosis antigens under diversifying evolutionary selection induce Th17 responses in human infection
Paul Ogongo, University of California San Francisco (USA)
Abstract | Presentation

A human infection/antigenic challenge model using pulmonary delivery of live BCG and PPD to gain insights into TB immunopathogenesis
Anil S. Pooran, University of Cape Town Lung Institute (South Africa)
Abstract

Assessing vaccine-mediated protection in an ultra-low dose Tuberculosis micobacteriana murine model
Courtney R. Plumlee, Seattle Children’s Research Institute (USA)
Abstract

Teatro de Câmara

OA2: Advancing clinical development

Details

Session Chairs: Alberto Garcia-Basteiro, CISM - ISGlobal (Mozambique) | Mark Hatherill, University of Cape Town (South Africa)

Efficiency of restricting participation in tuberculosis vaccine trials to interferon-gamma release assay-positive participants
Frank Cobelens, Amsterdam Institute for Global Health & Development (Netherlands)
Abstract | Presentation

Impact of BCG vaccination against Tuberculosis micobacteriana infection in adult healthcare workers: A nested clinical trial
Paulo Cesar Pereira dos Santos, Universidade Federal de Mato Grosso do Sul (Brazil)
Abstract | Presentation

Effectiveness of primary Bacillus Calmette-Guérin against the risk Tuberculosis micobacteriana infection and tuberculosis disease: an individual-participant meta-analysis of trials and observational studies
Puck Pelzer, IAVI (Netherlands)
Abstract | Presentation

A global epidemiologic study assessing interferon gamma release assay positivity in populations with high tuberculosis burden
Alemnew F. Dagnew, Gates Medical Research Institute (USA)
Abstract | Presentation

Immunogenicity of an investigational tuberculosis vaccine, M72/AS01E-4, in people living with HIV: a Phase 2, randomized, clinical trial
Lisa Deanne Schlehuber, Gates Medical Research Institute (USA)
Abstract

Challenges in recruiting neonates for a phase III TB vaccine trial and mitigations taken: Lessons learned for community engagement in Mbeya, Tanzania
Doreen Ibrahim Pamba, National Institute for Medical Research, Mbeya, Tanzania
Abstract | Presentation

13:00 - 14:00

Almuerzo

14:00 - 15:30

Grande Sala

Plenary 4: Country scale-up and implementation of new TB vaccines

Details

Session Chairs: Fernanda Dockhorn, Ministry of Health (Brazil) | Birgitte Giersing, World Health Organization (Switzerland)

Presentations and Speakers

Ensuring adequate supply to meet demand
Shelly Malhotra, IAVI (USA)
Presentation

Preparing for vaccine approval, scale-up and implementation - experience in South Africa
Norbert Ndjeka, National Department of Health (South Africa)
Presentation

Financing and procuring of new TB vaccines - the process in Brazil and the PAHO region
Thayssa Neiva de Fonseca Victer, Ministry of Health (Brazil)
Presentation

Engaging communities for the successful introduction of new TB vaccines: Communities and inclusion strategies
Patrick Agbassi, Global TB Cab, Côte d’Ivoire
Presentation

15:30 - 17:00

Grande Sala Foyer

Break | Poster Viewing

Haga clic aquí to view a list of posters and abstracts, as well as posters where permission was granted to post them.

17:00 - 18:00

Teatro de Câmara

Poster Discussion Sessions

PD1: Defining correlates of protection

Details

Moderators: David Lewinsohn, Oregon Health & Science University (USA) | Paul Ogongo, University of California San Francisco (USA)

Discussants

Elizabeth Church, Fred Hutchinson Cancer Center (USA)
A phase I single site open label clinical trial for the development of a human BCG challenge model to assess TB drugs and vaccines
Shuailin Li, University of Oxford (UK)
Characterising lung mucosal and systematic immune response in an aerosol BCG human challenge model using single cell sequencing
Simon Mendelsohn, Institute of Infectious Disease and Molecular Medicine, University of Cape Town (South Africa)
mRNA signatures measured prior to H56:IC31 vaccination predict TB relapse in HIV negative adults successfully treated for drug-susceptible pulmonary TB
Iman Satti, University of Oxford (UK)
Prior BCG vaccination protects against subsequent aerosol BCG challenge in UK adults
Monalisa Trentini, Instituto Butantan (Brazil)
Establishing a humanized mouse model to mimic human tuberculosis pathology for in vivo immunotherapy research
Elly van Riet, TBVI (Netherlands)
Development of a human lung-liver-lymph node co-culture on a chip for the screening of tuberculosis vaccine candidates

This is an interactive discussion session among authors whose posters share a common theme. Abstract titles are provided as a reference, but authors will not be giving formal presentations of their posters during this session. We encourage you to visit these posters and interact with the authors during the poster viewing session just before this discussion session.

Eletroacústica

PD2: Feeding the pipeline: New vaccines and platforms

Details

Moderators: Erica Chimara, Instituto Adolfo Lutz (Brazil) | Katrin Eichelberg, NIAID, NIH (USA)

Discussants

Ana Carolina Carvalho, Instituto Butantan (Brazil)
Recombinant BCG vaccine rBCG-LTAK63 enhances autophagy in innate immune cells
Zach Howard, University of California San Francisco (USA)
R Tuberculosis micobacteriana variable antigen vaccine induces infection tolerance
Lyudmila Kovalchuke, VIB-UGent (Belgium)
BAXERNA: Developing a next-generation mRNA vaccine against TB
Isabel Lamb-Echegaray, UC Berkeley (USA)
Mucosal vaccination with cyclic dinucleotide adjuvants induces effective T cell homing and IL-17-dependent protection against Mycobacterium tuberculosis infection which may be autophagy mediated
Smita Mehra, Texas Biomedical Research Institute (USA)
Investigating the role of Indoleamine dioxygenase in modulating immune responses to Tuberculosis micobacteriana
Elena Stylianou, University of Oxford (UK)
A multi-antigen subunit vaccine improves BCG efficacy in mice and non-human primates

Sala de Ensaio 3

PD3: Including and reaching populations with special considerations

Details

Moderators: Anastasia Koch, Eh!woza (South Africa) | Arinze Austin Obiefuna, Stop TB Partnership Board and Afro Global Alliance (Ghana)

Discussants

Crhistinne Cavalheiro Maymone Gonçalves, Faculdade de Medicina da Universidade Federal do Mato Grosso do Sul (Brazil)
Perceptions of the incarcerated population regarding tuberculosis research and vaccines
Monica Magalhaes, Rutgers University (USA)
The ethics of including persons deprived of liberty in tuberculosis vaccine trials
Edna Tembo, Coalition of Women Living with HIV/AIDS (COWLHA) (Malawi)
Community Consensus and Call to Action on Inclusion of Pregnant and Breastfeeding Women and Persons in TB Vaccine Trials
Rupali Limaye, Johns Hopkins Bloomberg School of Public Health
Willingness to receive a future TB vaccine among pregnant women living in Brazil, Ghana, Kenya, and Pakistan
James Eghaghe, Nigeria Network of People who Use Drugs - NNPUD (Nigeria)
A study Of knowledge and experiences about tuberculosis infection amongst persons who use and inject drugs (PWUIDs) in Lagos, Oyo, Ogun States -South Western Nigeria
Martha Nyakambi, PHDA (Kenya)
Enhancing community engagement in tuberculosis vaccine delivery among key populations: A qualitative study

18:00 - onward

Tarde libre

Thursday, 10 October 2024

08:30 - 09:00

Arrival | Coffee | Networking

09:00 - 11:00

Grande Sala

Plenary 5: Innovative approaches to TB vaccine development

Details

Session Chairs: Hazel Dockrell, London School of Hygiene & Tropical Medicine (UK) | Luciana Leite, Instituto Butantan (Brazil)

Mucosal BCG delivery to improve beyond the limits of a successful TB vaccine
Frank Verreck, TB Research & Immunology, Biomedical Primate Research Centre (Netherlands)
Presentation

Investigating correlates of protection after IV BCG immunization
Patricia A. Darrah, Vaccine Research Center, National Institutes of Health (USA)
Presentation

Immune correlates of protection in human TB vaccine trials
Elisa Nemes, SATVI, University of Cape Town (South Africa)

Establishing a controlled human infection model for TB
Helen McShane, University of Oxford (UK)
Presentation

Community Perspective
Ezio Távora, REDE-TB (Brazil)

11:00 - 11:30

Pausa

11:30 - 13:00

Oral Abstract Sessions

Grande Sala

OA3: Improved formulation and delivery platforms, preclinical research

Details

Session Chairs: Tiemi Arakawa, Ministry of Health (Brazil) | Willem Hanekom, Africa Health Research Institute (South Africa)

Development of a novel self-adjuvanting mucosal vaccine for TB
Andy C. Tran, St. George’s, University of London (UK)
Abstract | Presentation

A novel TB mRNA vaccine using targeted lipid nanoparticles generates CD4 and CD8 T cell responses that protect against infection in an ultra-low dose aerosol infection mouse model
Ross Fulton, Akager Medicines, Inc. (USA)
Abstract | Presentation

Protective efficacy of a novel protein adjuvanted formulation PPE15-LMQ: A promising tuberculosis vaccine candidate
Marcellus Korompis, Oxford University (UK)
Abstract

Strategically targeting mucosal immunity increases the effectiveness of tuberculosis vaccines
Marcela I. Henao-Temayo, Colorado State University (USA)
Abstract

Preclinical evaluation of TA system based attenuated mutant strains as TB vaccine candidates
Ramandeep Singh, THSTI (India)
Abstract

DsigH, an attenuated Mycobacterium tuberculosis Mutant, prevents tuberculosis via efficient antigen presentation and iBALT formation
Dhiraj K. Singh, Texas Biomedical Research Institute (USA)
Abstract

Teatro de Câmara

OA4: Impact, implementation, policy

Details

Session Chairs: Suvanand Sahu, Stop TB Partnership (Switzerland) | Pedro Eduardo Almeida da Silva, Universidade Federal do Rio Grande and REDE-TB (Brazil)

Facing up to reality—What to do if M72/AS01E doses are limited?
Rebecca A. Clark, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine (UK)
Abstract | Presentation

Willingness to receive a future adult tuberculosis vaccine in Lusaka, Zambia: Perspectives from community members and healthcare workers
Andrew D. Kerkhoff, Division of HIV, Infectious Diseases and Global Medicine, Zuckerberg General Hospital at the University of California San Francisco (USA)
Abstract | Presentation

Cost and cost-effectiveness of novel tuberculosis vaccines in Africa: A systematic review of modelling studies
Fortune Benjamin Effiong, Medical Laboratory Science (Nigeria)
Abstract | Presentation

Advancing evidence-informed in-country decision-making for new TB vaccine introduction: A responsive and integrated vaccine modelling approach from India
Jessy Joseph, IAVI (India)
Abstract | Presentation

From hesitation to implementation: Empowering Pakistan's health system for TB preventive treatment success
Kinz ul Eman, Dopasi Foundation (Pakistan)
Abstract | Presentation

Protecting investment in TB vaccine R&D and health systems amid debt distress and reform
Erin V. McConnell, Treatment Action Group (USA)
Abstract | Presentation

13:00 - 14:00

Almuerzo

14:00 - 15:00

Sesiones de discusión

Grande Sala

DS1: Accelerating clinical development of novel TB vaccines

Details

Teatro de Câmara

DS2: From political commitment to action to deliver new TB vaccines this decade

Details

Organized by the TB Vaccine Advocacy Roadmap (TB Vax ARM)

Moderators: Shaun Palmer, IAVI and TB VAX ARM (Netherlands) | Carla Almeida, Brazilian TB CAB (Brazil)

Panelists:

Mike Frick, Treatment Action Group (USA)
Edna Tembo, Coalition of Women & Girls Living with HIV and AIDS (COWLHA) (Malawi)
Phorng Chanthorn, Khmer HIV/AIDS NGO Alliance (KHANA) (Cambodia)
Leigh Rathby, Results Canada (Canada)
David Lewinsohn, Working Group on New TB Vaccines (USA)

15:00 - 15:15

Pausa

15:15 - 16:15

Grande Sala

Plenary 6: Enabling TB vaccine development through funding, political will, open science, and engaged communities

Details

16:15 - 17:00

Grande Sala

Closing Session

Details

Friday, 11 October 2024

Various

Visitas sobre el terreno

Details

Speakers retain the copyright and intellectual property rights on their respective information, documents, files, presentations, and other content shared during the event.